Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors
Funded at Sloan-Kettering Inst Can Research · NIH-11534528 · Data updated 2026-11-12
A program uses mouse tumor models to identify promising drug candidates for children with sarcoma and other solid tumors.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2026 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $363,703 |
| NIH project number | 3U01CA263967-05S1 |
| Project ID | NIH-11534528 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children and adolescents with bone/soft tissue sarcomas, renal tumors, DSRCT, or other rare pediatric solid tumors.
✕Less likely to help
The program is preclinical and may not benefit all patients; some drugs identified may not translate to effective pediatric therapies.
What this research studies
This project leverages a large bank of genomically characterized pediatric tumor models to test cancer drugs in vivo. It plans to work with multiple institutions to prioritize agents for pediatric trials based on preclinical results. The team will coordinate with disease committees to select appropriate agents and models and move promising therapies toward clinical testing. The focus is on pediatric bone and soft tissue sarcomas, renal tumors, and rare solid tumors, including desmoplastic small round cell tumor. The work aims to bridge preclinical findings with children’s clinical trials to accelerate potential treatments.
Why it matters
Potential benefit: If successful, this program could speed up the identification of effective drugs for children with hard-to-treat cancers and guide which therapies should enter pediatric trials.
How similar studies have gone: Previous work with pediatric PDX models has shown that preclinical testing can inform which agents deserve clinical investigation, though translation to efficacy in patients varies by drug.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Kung, Andrew L — Sloan-Kettering Inst Can Research
- Study coordinator: Kung, Andrew L
Related research
Other NIH-funded projects on the same topics.
-
Finding New Treatments for Childhood Sarcoma and Rare Cancers
This work aims to discover new drug options for children facing sarcomas and other rare solid tumors.
-
Testing new cancer treatments for children with solid tumors
This study is looking for better cancer treatments for kids with solid tumors, like certain sarcomas and rare cancers, by testing new drugs on models created from real patient samples, so that doctors can find the best options for young patients.
-
Testing new therapies for pediatric and young adult sarcoma, kidney, and liver cancers
Researchers are testing new drugs and smart combinations in models of pediatric cancers to help guide future treatments for kids and young adults.
-
Precision 3D Imaging to Monitor Kaposi Sarcoma (KS) with SkinScan3D
A new portable 3D imaging tool called SkinScan3D will help doctors measure KS skin lesions more accurately and quickly, especially in people living with HIV.
-
Precision 3D Imaging to Track Kaposi Sarcoma (KS) with SkinScan3D
A new 3D imaging tool called SkinScan3D helps doctors monitor Kaposi sarcoma lesions more accurately and quickly, especially in settings with high KS burden like East Africa and in U.S. clinics with HIV patients.
-
Rapid, bedside KS diagnosis in Africa with KS-COMPLETE
A fast, point-of-care test using skin biopsies to diagnose Kaposi’s sarcoma in sub-Saharan Africa, helping patients get results in about an hour.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.